Learn more about how Mayo Clinic Laboratories’ genetic testing for pancreatic disease can provide a clearer understanding of a patient’s condition.
Malabsorption disorders - Insights
Malabsorption syndrome encompasses several disorders that impact the ability of the small intestine to absorb macronutrients, micronutrients, or both. Because malabsorption syndrome can be caused by myriad factors, identifying the...
Assay stratifies pregnant women's preeclampsia risk: Joshua Bornhorst, Ph.D. - Insights
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal...
New tests launched in July - Insights
In July 2022, Mayo Clinic Laboratories announced fifteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Rapid hereditary breast cancer - Insights
Learn how our rapid breast cancer treatment panel delivers results in 10 to 14 days and detects 11 genes linked to lifetime breast cancer risk.
MayoLINK Universal Test Management Solution - Mayo Clinic Laboratories
MayoLINK Universal Test Management Solution - Mayo Clinic Laboratories Share Print...
Prenatal - Mayo Clinic Laboratories
Share Print Web: mayocliniclabs.com...
Mayo Clinic Labs @Work: Daniel Kronemann - Insights
As a clinical laboratory technologist, Daniel Kronemann enjoys going beyond his day-to-day work as he explores new ways to enhance processes and systems in Bacteriology.
Learn more about how direct ethanol biomarker testing at Mayo Clinic Laboratories provides heightened sensitivity and specificity to accurately assess alcohol use and alcohol use disorder.
New tests launched in August - Insights
In August 2022, Mayo Clinic Laboratories announced thirty-two new tests along with numerous reference value changes, obsolete tests, and algorithm changes.